154 related articles for article (PubMed ID: 38525919)
1. Analytical Performance Evaluation of a Digital Real-Time PCR for Quantifying Major BCR::ABL1 Transcripts.
Lee SJ; Lee JM; Ahn A; Lee SE; Hong Y; Lee GD; Song HW; Song MS; Shin SS; Kim M; Kim Y
J Clin Lab Anal; 2024 Apr; 38(7):e25034. PubMed ID: 38525919
[TBL] [Abstract][Full Text] [Related]
2. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
3. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
[TBL] [Abstract][Full Text] [Related]
4. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
5. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
[TBL] [Abstract][Full Text] [Related]
7. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.
Furuya D; Moriai M; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
Int J Clin Oncol; 2019 Jul; 24(7):871-875. PubMed ID: 30798394
[TBL] [Abstract][Full Text] [Related]
8.
Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
10. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
Brown JT; Beldorth IJ; Laosinchai-Wolf W; Fahey ME; Jefferson KL; Ruskin AK; Roth JJ; Cai L; Watt CD; Press RD; Yang F; Hedges JB; Andruss BF
J Mol Diagn; 2019 Jul; 21(4):718-733. PubMed ID: 31026597
[TBL] [Abstract][Full Text] [Related]
11. Qualitative and quantitative evaluation of the BCR-ABL fusion gene in chronic myelogenous leukemia by flourescence in situ hybridization and molecular genetic methods.
Ozemri Sag S; Yakut T; Gorukmez O; Gorukmez O; Ture M; Karkucak M; Gulten T; Ali R
Genet Test Mol Biomarkers; 2015 Oct; 19(10):584-8. PubMed ID: 26308792
[TBL] [Abstract][Full Text] [Related]
12. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR.
Jennings LJ; George D; Czech J; Yu M; Joseph L
J Mol Diagn; 2014 Mar; 16(2):174-9. PubMed ID: 24389534
[TBL] [Abstract][Full Text] [Related]
13. Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia.
Shelton DN; Bhagavatula P; Sepulveda N; Beppu L; Gandhi S; Qin D; Hauenstein S; Radich J
PLoS One; 2022; 17(3):e0265278. PubMed ID: 35298544
[TBL] [Abstract][Full Text] [Related]
14. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of childhood ALL using
Hovorkova L; Zaliova M; Venn NC; Bleckmann K; Trkova M; Potuckova E; Vaskova M; Linhartova J; Machova Polakova K; Fronkova E; Muskovic W; Giles JE; Shaw PJ; Cario G; Sutton R; Stary J; Trka J; Zuna J
Blood; 2017 May; 129(20):2771-2781. PubMed ID: 28331056
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
17. Molecular Monitoring of Chronic Myeloid Leukemia.
Dominy K; Mokretar K; Reid AG; Khorashad JS
Methods Mol Biol; 2020; 2065():153-173. PubMed ID: 31578694
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.
Huang YJ; Kuo MC; Jaing TH; Liu HC; Yeh TC; Chen SH; Lin TL; Yang CP; Wang PN; Sheen JM; Chang TK; Chang CH; Hu SF; Huang TY; Wang SC; Wu KH; Chiou SS; Hsiao CC; Shih LY
J Mol Diagn; 2021 Oct; 23(10):1373-1379. PubMed ID: 34325057
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of tyrosine kinase inhibitors based on
Kim Y; Kim S; Lee JM; Ahn A; Yoo JW; Lee JW; Cho B; Chung NG; Kim Y; Kim M
Front Pediatr; 2022; 10():928136. PubMed ID: 35967571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]